One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

With U.S. stock markets set to open in two hours, Doximity Inc. (DOCS) was up 24.5% in pre-market trading, and Pinterest Inc. (PINS) was up 20.1%.

BofA lowered the firm’s price target on Neurocrine (NBIX) to $179 from $184 and keeps a Buy rating on the shares after the company reported Q4 ...

Management guided INGREZZA sales to reach between $2.5 billion and $2.6 billion in 2025, supported by an expanded sales force and ongoing direct-to-consumer initiatives. This guidance reflects ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.